# Clariant agrees to acquire Lucas Meyer Cosmetics

# Clariant Third Quarter / Nine Months Figures 2023

Analyst and investor presentation



30.10.2023



# **Disclaimer**

This presentation contains certain statements that are neither reported financial results nor other historical information.

This presentation also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements.

Many of these risks and uncertainties relate to factors that are beyond Clariant's ability to control or estimate precisely, such as future market conditions, geopolitical dislocation, currency fluctuations, the behavior of other market participants, the actions of governmental regulators, and other risk factors, such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social, and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation, and consumer confidence, on a global, regional, or national basis.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document.

Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.





# Lucas Meyer Cosmetics ("LMC") – proven success story in high value consumer applications

**High quality** ~ USD 100 m 81 + Sizeable, pure-play cosmetic ingredients asset 2 900 + customers Countries served Sales ~ 14 years **Direct sales** ~ 195 Highly experienced leadership team with excellent track record Average tenure<sup>1</sup> In 9 countries **Employees globally** 150 +40 + Portfolio backed by science and based on natural ingredients Patent families R&D labs **Products** 50 +CMO **High-end brands** Differentiated, highly innovative business model Based production Solution provider Innovation awards ~ 10 % Highly attractive Highly cash Superior growth, profitability and cash generation Sales growth<sup>2</sup> profitability generative

<sup>&</sup>lt;sup>1</sup> Average tenure of executive leadership team

<sup>&</sup>lt;sup>2</sup> Sales growth CAGR 2015-2023E

# Compelling rationale enhancing Clariant's specialty focus

- 1 Fully aligned with Clariant's purpose-led growth strategy will strengthen our position as a true specialty chemical company
- 2 Highly attractive business with clear competitive edge asset light business model with proven track record
- 3 Accelerating sustainability and innovation agenda highly innovative business with impeccable sustainability credentials
- Increasing exposure to most attractive consumer end-markets fast-growing luxury cosmetic ingredients segment
- 5 Highly complementary businesses, underpins growth and de-risks execution strong fit across customers, products and regions
- Tangible value creation for Clariant shareholders underpinned by ambition to grow LMC sales to ~ USD 180 m by 2028

# Attractive terms proposed, secured financing and rapid path to closing

Attractive terms	<ul> <li>Total consideration: USD 810 m (~ CHF 720 m¹) on a cash-free, debt-free basis, payable in cash at closing</li> <li>EV/EBITDA multiple: 16.3x²</li> <li>EPS accretion: mid-single digit percentage accretive from year 1 onwards³</li> </ul>
Secured financing	<ul> <li>Funding structure: fully committed acquisition bridge facility, to be refinanced swiftly after closing</li> <li>Financial leverage: expected to increase modestly to ~ 2.8x net debt/EBITDA<sup>4</sup></li> <li>Credit rating: no change expected in credit rating (investment grade)</li> </ul>
Rapid path to closing	<ul> <li>Timing of closing: closing expected in first quarter of 2024</li> <li>Conditions precedent: customary closing conditions, inc. antitrust clearance</li> <li>Segment reporting: Lucas Meyer Cosmetics will be reported as part of the Business Unit Care Chemicals</li> </ul>

<sup>&</sup>lt;sup>1</sup> USDCHF FX of 0.89

<sup>&</sup>lt;sup>2</sup> LTM August 2023; reported

<sup>&</sup>lt;sup>3</sup> On an adjusted basis including full run-rate synergies and excluding non-recurring, transaction-related costs

<sup>&</sup>lt;sup>4</sup> On completion

# E

# 1 Fully aligned with Clariant's purpose-led growth strategy

# **Purpose-led strategy**

Customer focus



Innovative chemistry



Leading in sustainability



People engagement



Clariant's purpose: "Greater chemistry – between people and planet"

Value enhancing M&A					
	Communicated criteria	Lucas Meyer Cosmetics			
Attractive end markets	<ul> <li>Attractive market position</li> <li>Focus on Consumer Care, Catalysts, Additives and Purification</li> </ul>	✓			
Sustainable technologies	<ul><li>Complementing Clariant's technologies</li><li>Positive sustainability impact</li></ul>	✓			
Augmenting footprint	<ul><li>Revenue synergies</li><li>Product line extensions</li><li>New regions</li></ul>	✓			
Accelerating growth	<ul> <li>M&amp;A contributing ~ 0.75 % p.a. to 2025 target of 4 - 6 % growth p.a.</li> </ul>	✓			
Accretive financial profile	<ul><li>EPS accretive</li><li>Growth, profitability and cash flow enhancing</li></ul>	✓			

# E

# 2 Highly attractive business with clear competitive edge,3 accelerating sustainability and innovation agenda

## Industry leading product portfolio



**Active ingredients** 

- Broad portfolio of peptides, created through synthesis of amino acids and have anti-ageing, moisturizing, firming tightening
- · Largely custom-made/specialized solutions



- Phospholipid based emulsifiers and gelling agents serving as surfactants and texturizers
- Largely custom-made/specialized solutions




- Botanicals are plant-based extracts
- Includes natural actives and Australian Botanicals
- · Inhouse raw material production & manufacturing



- Phospholipid based encapsulations enhancing active ingredients stability & release
- Offering combined with other own products & ingredients

# Innovation flywheel




# Sustainability

Source responsibly


Design safe, naturally derived & biodegradable ingredients


Foster circular solutions

# 4 Increasing exposure to most attractive consumer end-markets



# 5 Highly complementary and synergistic businesses





Better positioning in the active ingredients market

- · Valuable addition to our own care ingredients portfolio
- · Establish market leading position in the active ingredients space
- · Further strengthens overall Home & Personal Care offering

Complementary business, offering cross-selling opportunities

- LMC will offer a complementary fit to our product portfolio and customer portfolio
- Value in growing together, building on Clariant's multi-year track record of integrating bolt-on acquisitions

- Diversified investment with increased exposure to North American market
- Will improve position in highly attractive end-markets in North America
- Access to LMC's marketing, go-to-market and new-product launch capabilities
- LMC to access Clariant's global footprint and customer base

Ambition to grow LMC sales from ~ USD 100 m to ~ USD 180 m by 2028

<sup>&</sup>lt;sup>1</sup> Converted at USDCHF spot rate of 0.89



# **6** Tangible value creation for Clariant shareholders proposed

	Clariant financial targets	Lucas Meyer Cosmetics
Sales growth	4 - 6 %	<b>√</b> ~ 10 %¹
EBITDA margin	19 - 21 %	✓ Highly attractive profitability
Cash conversion	~ 40 % FCF	✓ Highly cash generative
Capital structure	Investment grade credit rating	✓ Unchanged

Mid-single digit percentage EPS accretive from year 1 onwards<sup>2</sup>


<sup>&</sup>lt;sup>2</sup> On an adjusted basis including full run-rate synergies and excluding non-recurring, transaction-related costs

# **Closing remarks**

- Fully aligned with Clariant's purpose-led growth strategy
- Highly attractive business with clear competitive edge
- Accelerating sustainability and innovation agenda
- Increasing exposure to most attractive consumer end-markets
- Highly complementary businesses, underpins growth and de-risks execution
- **Tangible value creation for Clariant shareholders**




# Q3 sales: Catalyst growth, stabilization in Care Chemicals, and continued challenges in Additives – FX and Scope impacting top-line




# E

# Q3 EBITDA: Strong margin performance in Catalysts – Care Chemicals and Additives impacted by FX and volume



# Sequential development: slightly positive volumes compensated pricing; cost measures and operational improvement supported profitability



<sup>&</sup>lt;sup>1</sup> Excluding CHF 62 m preliminary Quats gain, CHF - 18 m restructuring, and CHF - 5 m others from reported CHF 175 m in Q2 2023;


<sup>&</sup>lt;sup>2</sup> Excluding CHF - 1 m gain/loss on disposals, CHF - 1 m restructuring, and CHF - 3 m others from reported CHF 159 m in Q3 2023



# Third Quarter 2023 Care Chemicals

in CHF m	Q3 2023	Q3 2022	% CHF	% LC¹
Sales	525	725	- 28	- 18
EBITDA	91	144	- 37	
EBITDA margin	17.3 %	19.9 %		
EBITDA b.e.i. <sup>2</sup>	92	144	- 36	
EBITDA b.e.i. <sup>2</sup> margin	17.5 %	19.9 %		

	Q3 2023
Volumes	- 2 %
Price	- 6 %
Currency	- 10 %
Scope	- 10 %




# **Highlights**


- Volume declined slightly year-on-year versus high comparison base due to weak demand; up 7 % sequentially with continued monthly improvement during the quarter
- Pricing lower due to index-based price adjustments linked to raw material prices; pricing down 3 % sequentially
- Segments: Strongest decline in Crop Solutions, followed by Industrial Applications, Mining and Base Chemicals (teen percentage range organic). Personal & Home Care down by mid single-digits and Oil Services up in high teens organically
- Organic growth APAC, including China, at a high single digit percentage rate, Americas flat, and EMEA lower
- EBITDA year-on-year impacted by operating leverage (volume) and currency translation – strong sequential underlying improvement

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# Third Quarter 2023 Catalysts

in CHF m	Q3 2023	Q3 2022	% CHF	% LC¹
Sales	260	262	- 1	8
EBITDA	58	30	93	
EBITDA margin	22.3 %	11.5 %		
EBITDA b.e.i. <sup>2</sup>	58	31	87	
EBITDA b.e.i. <sup>2</sup> margin	22.3 %	11.8 %		





# **Highlights**

- Volume growth in Propylene and Syngas & Fuels;
   continued positive pricing; sequentially lower due to project nature
- Segments: Strong growth in Propylene and Syngas & Fuels (both > 40 %), while Specialties and Ethylene declined
- Regional dynamics driven by project nature, strong growth in Americas and EMEA, and growth in China
- EBITDA impacted by continued positive pricing, better business mix, and higher operating leverage (volumes)
- sunliquid<sup>®</sup> effect
  - CHF 11 m operational impact in Q3 2023
  - CHF 2 m yoy improvement
- → 26.5 % EBITDA margin, excluding sunliquid®


<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items



# Third Quarter 2023 Adsorbents & Additives

		2		
in CHF m	Q3 2023	Q3 2022	% CHF	% LC¹
Sales	246	325	- 24	- 19
EBITDA	30	79	- 62	
EBITDA margin	12.2 %	24.3 %		
EBITDA b.e.i. <sup>2</sup>	30	79	- 62	
EBITDA b.e.i. <sup>2</sup> margin	12.2 %	24.3 %		

Q3 2023
- 20 %
- 1 %
- 5 %
+ 2 %



# **Highlights**


 Volume declined significantly and pricing was slightly negative, both primarily driven by Additives. Sequentially, price and volume declined by low single-digit percentage

# - Segments:

- Additives down by low-forties percentage rate against high comparison base, as demand in key end markets remained very weak
- Adsorbents up by mid single-digit percentage rate, driven by foundry business, supported by scope
- All regions declined, led by Asia-Pacific (Additives)
- EBITDA impacted by lower operating leverage, fixed cost absorption (Additives), and business mix

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# On track to achieve total cost savings of CHF 170 m by 2025 – Q3 2023 delivered additional CHF 14 m savings





Outlook 2023

# Outlook 2023: Confirming outlook despite challenging macroeconomic environment and currency headwinds

# 2023 Sales Range (CHF) EBITDA Range (CHF) CHF 650 – 700 m (margin 14.3 % – 15.1 %)

(5.2 bn in 2022)

(margin 15.6 % in 2022)

## Confirmed commitment towards 2025 financial targets







Profitable sales growth (4 – 6 % CAGR)

Group EBITDA margin between 19 – 21 %

Free cash flow conversion of around 40 %

### **Internal Factors**

- Softening pricing in recessionary/deflationary economic environment
- Execute new operating model delivery of restructuring savings
- Total top-line net impact of CHF 150 m (divestments/acquisition)
- Further improvement of sunliquid<sup>®</sup> performance
- Capex: targeted below CHF 220 m in 2023

### **External Factors**

- Soft recessionary environment expected in Q4 2023
- Moderation in general inflation
- No indication of an economic recovery in Q4 2023, uncertainties and risks remain
- China recovery at a slow pace
- Upper end of negative 5 10 % FX translation impact
- Q4: Lower raw material costs expected yoy;
   lower energy costs expected yoy but higher sequentially



# Third Quarter 2023 – Overview

## Group

in CHF m	Q3 2023	Q3 2022	% CHF	% LC <sup>1</sup>
Sales	1 031	1 312	- 21	- 13
EBITDA	159	220	- 28	
EBITDA margin	15.4 %	16.8 %		
EBITDA b.e.i. <sup>2</sup>	164	242	- 32	
EBITDA b.e.i. <sup>2</sup> margin	15.9 %	18.4 %		
Sales Bridge	<b>Price</b> - 3 %	<b>Volume</b> - 5 %	Currency - 8 %	<b>Scope</b> - 5 %

# **Catalysts**

in CHF m	Q3 2023	Q3 2022	% CHF	% LC <sup>1</sup>
Sales	260	262	- 1	8
EBITDA	58	30	93	
EBITDA margin	22.3 %	11.5 %		
EBITDA b.e.i. <sup>2</sup>	58	31	87	
EBITDA b.e.i. <sup>2</sup> margin	22.3 %	11.8 %		
Sales Bridge	Price 4 %	Volume 4 %	Currency - 9 %	Scope 0 %

**Care Chemicals** 

in CHF m	Q3 2023	Q3 2022	% CHF	% LC <sup>1</sup>
Sales	525	725	- 28	- 18
EBITDA	91	144	- 37	
EBITDA margin	17.3 %	19.9 %		
EBITDA b.e.i. <sup>2</sup>	92	144	- 36	
EBITDA b.e.i. <sup>2</sup> margin	17.5 %	19.9 %		
Sales Bridge	<b>Price</b> - 6 %	Volume - 2 %	Currency - 10 %	<b>Scope</b> - 10 %

### **Adsorbents & Additives**

in CHF m	Q3 2023	Q3 2022	% CHF	% LC¹
Sales	246	325	- 24	- 19
EBITDA	30	79	- 62	
EBITDA margin	12.2 %	24.3 %		
EBITDA b.e.i. <sup>2</sup>	30	79	- 62	
EBITDA b.e.i. <sup>2</sup> margin	12.2 %	24.3 %		
Sales Bridge	<b>Price</b> - 1 %	<b>Volume</b> - 20 %	Currency - 5 %	Scope 2 %

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# Nine Months 2023 – Overview

# Group

in CHF m	9M 2023	9M 2022	% CHF	% LC <sup>1</sup>
Sales	3 315	3 875	- 14	- 7
EBITDA	501	656	- 24	
EBITDA margin	15.1 %	16.9 %		
EBITDA b.e.i. <sup>2</sup>	483	690	- 30	
EBITDA b.e.i. <sup>2</sup> margin	14.6 %	17.8 %		
Sales Bridge	Price	<b>Volume</b> - 6 %	Currency - 7 %	<b>Scope</b> - 2 %

# **Catalysts**

in CHF m	9M 2023	9M 2022	% CHF	% LC <sup>1</sup>
III CHF III	9IVI 2023	9IVI 2022	% СПГ	% LC
Sales	742	679	9	18
EBITDA	113	57	98	
EBITDA margin	15.2 %	8.4 %		
EBITDA b.e.i. <sup>2</sup>	122	59	107	
EBITDA b.e.i. <sup>2</sup> margin	16.4 %	8.7 %		
Sales Bridge	Price 4 %	<b>Volume</b> 14 %	Currency - 9 %	<b>Scope</b> 0 %

**Care Chemicals** 

in CHF m	9M 2023	9M 2022	% CHF	% LC <sup>1</sup>
Sales	1 771	2 223	- 20	- 12
EBITDA	352	435	- 19	
EBITDA margin	19.9 %	19.6 %		
EBITDA b.e.i. <sup>2</sup>	299	435	- 31	
EBITDA b.e.i. <sup>2</sup> margin	16.9 %	19.6 %		
Sales Bridge	<b>Price</b> 0 %	<b>Volume</b> - 7 %	Currency - 8 %	<b>Scope</b> - 5 %

### **Adsorbents & Additives**

in CHF m	9M 2023	9M 2022	% CHF	% LC¹
Sales	802	973	- 18	- 12
EBITDA	102	241	- 58	
EBITDA margin	12.7 %	24.8 %		
EBITDA b.e.i. <sup>2</sup>	110	242	- 55	
EBITDA b.e.i. <sup>2</sup> margin	13.7 %	24.9 %		
Sales Bridge	<b>Price</b> 3 %	<b>Volume</b> - 17 %	Currency - 6 %	Scope 2 %

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# **Third Quarter 2023 Strategic Priorities**

# - sunliquid®


- Operational EBITDA impact of CHF 11 m in Q3 2023
- Sequentially similar level in Q4 2023 expected
- Continued efforts to address ramp-up challenges in Podari
- Actively evaluating strategic options for sunliquid® update by end of 2023

## Performance programs

- On track for revised 2025 targeted savings of CHF 170 m, achieved CHF 121 m savings as of Q3 2023
- CHF 14 m additional savings delivered in Q3 2023 across the performance programs in the business units and corporate

## Successful refinancing of Swiss Bonds


- CHF 150 m senior unsecured bond at 2.75 % fixed rate
- Five-year tenor (2023 2028)
- Investment grade rating: "BBB-" by Standard & Poor's



# **Geographic split**

### Q3 sales CHF 1031 m

in CHF m, % year-on-year in local currency




# Regional headline

- While absolute sales in the **Americas** declined, organic growth was 4 %, driven by Catalysts in the US. Decline in Brazil mainly attributable to scope
- EMEA sales declined as mid-teens percentage (volume) growth in Catalysts coming from the Middle East did not offset declines in Care Chemicals and Adsorbents & Additives
- Asia-Pacific sales declined, with a less pronounced decrease in China, due to lower sales in Adsorbents & Additives and Catalysts in particular

# **Geographic split**

### 9M sales CHF 3 315 m

in CHF m, % year-on-year in local currency




# Regional headline

- Sales in the **Americas** were lower due to divestments as well as force majeure declarations in the first quarter, despite the positive contribution from the Attapulgite integration
- EMEA sales were lower, as strong growth from Catalysts in the Middle East could not offset the impact of weak demand in Germany on Care Chemicals and Adsorbents & Additives
- Asia-Pacific sales declined; the slow pace of recovery in China was most notable in Additives; Catalysts grew

# E


# Cost dynamics – lower year-onyear and sequentially

- Raw materials decreased year-on-year (sequential 7 %)
- Energy down year-on-year (sequential 1 %)
- Logistics lower year-on-year (sequential flat)



# Flat pricing – Volumes impacted by macro environment

- Recessionary economic environment in Q3
- Pricing slightly down, positive in CA while declining in CC (indexbased price adjustments) and AA
- Volumes down primarily due to AA (- 20 %); CC only had slight decrease (- 2 %); growth in CA (+ 4 %)
- Sequentially, pricing 2 % with volumes slightly up
- Weak consumer and industrial demand



# Reporting aligned with new operating structure as of Q1 2023



# **Business Unit Care Chemicals (CC)**

Segments include Personal & Home Care, Crop Solutions, Industrial Applications, Base Chemicals, Oil Services, and Mining Solutions



# **Business Unit Catalysts (CA)**

Segments include Propylene, Specialties, Syngas & Fuels, Ethylene, and Biofuels & Derivatives



### **Business Unit Adsorbents & Additives (AA)**

Segments include Adsorbents, Coatings & Adhesives, Plastics, and E-mobility & Electronics

**Key financial figures 2022** 

Sales CHF 2937 m 19.5 % EBITDA margin

Sales CHF 989 m 9.4 % EBITDA margin

Sales CHF 1272 m 21.7 % EBITDA margin





# 2022 - Reflecting Business Unit Structure as of 1 Jan 2023


SALES and EBITDA reported & before exceptional items (b.e.i.)

in CHF m		Q1 2022			Q2 2022			Q3 2022			Q4 2022			FY 2022	
	Sales	EBITDA reported	EBITDA b.e.i.												
Care Chemicals <sup>1</sup>	758	149	151	740	142	140	725	144	144	714	138	143	2 937	573	578
margin		19.7 %	19.9 %		19.2 %	18.9 %		19.9 %	19.9 %		19.3 %	20.0 %		19.5 %	19.7 %
Catalysts <sup>2</sup>	185	14	14	232	13	14	262	30	31	310	36	39	989	93	98
margin		7.6 %	7.6 %		5.6 %	6.0 %		11.5 %	11.8 %		11.6 %	12.6 %		9.4 %	9.9 %
Adsorbents & Additives <sup>3</sup>	319	83	83	329	79	80	325	79	79	299	35	39	1 272	276	281
margin		26.0 %	26.0 %		24.0 %	24.3 %		24.3 %	24.3 %		11.7 %	13.0 %		21.7 %	22.1 %
Business Units Total	1 262	246	248	1 301	234	234	1 312	253	254	1 323	209	221	5 198	942	957
Corporate		- 26	- 10		- 18	- 24		- 33	- 12		- 55	- 18		- 132	- 64
Total Contin. Operations	1 262	220	238	1 301	216	210	1 312	220	242	1 323	154	203	5 198	810	893
margin		17.4 %	18.9 %		16.6 %	16.1 %		16.8 %	18.4 %		11.6 %	15.3 %		15.6 %	17.2 %

<sup>1</sup>BU Care Chemicals includes former BA Care Chemicals and BU Oil & Mining Services; 2BU Catalysts unchanged from former BA Catalysis; 3BU Adsorbents & Additives includes former BU Functional Minerals and BU Additives

# Exposure to attractive consumer markets... ...with accelerating demand for sustainable products

Sales by end market (Q3 2023 LTM<sup>1</sup>)



<sup>&</sup>lt;sup>1</sup> Last Twelve Months (Q4 2022 – Q3 2023)

# **ESG – Clariant's Sustainability Transformation Commitment**

## Sustainability priorities

# **Fighting Climate Change**

Reducing our own carbon footprint and creating value for customers with low-carbon, high-performing solutions

# Zero Waste and Pollution

Eliminating waste and pollution from our operations and value chains



Safe and sustainable in everything we do

# Sustainable **Bio-economy**

Creating a sustainable bio-economy by protecting nature and maintaining high social standards


# **Increasing Circularity**

Products and solutions that enable reducing, reusing, and recycling

# **Social Value Creation**

Creating value for our employees, in our business networks, and in society as a whole

## Investment in operations & portfolio



### Sustainable operations


Future-proof our operations for a climateneutral, sustainable world



# **Sustainability-driven** portfolio change


Increase the safety and sustainability of our products and help our customers achieve their sustainability goals

# ESG update – Q3 2023 milestones / examples



# Continued progress on the path to 2030 greenhouse gas (GHG) target


Reducing our carbon footprint...



Scope 1 & 2 GHG emissions

in m tCO<sub>2</sub>e, corresponding to - 16 % since 2019

...and the carbon footprint of our raw materials



Scope 3 GHG emissions from purchased goods and services


in m tCO<sub>2</sub>e, corresponding to - 17 % since 2019

# Clariant is well recognized as an industry leader by important ESG ratings and rankings

Status as of October 2023

Index / Ranking / Rating	Clariant score / Percentile rank or range	Status / Comments		First year of inclusion
Member of Dow Jones Sustainability Indices Powered by the S&P Global CSA	₹ 72 / 97 <sup>th</sup> percentile	DJSI Europe Member, Sustainability Yearbook 2023 member	Sustainability Yearbook Member S&P Global ESG Score 2022	2012
SUSTAINALYTICS	20.8 (Medium risk) / 94 <sup>th</sup> percentile	Leader (compared to industry peers)	Legend         Rank   Percentile (1st = Top Score)           ● Industry (Chemicals)         32 / 562   6th	2016
MSCI ∰	= AA / Range: AAA to CCC	Second best score	22% 18% 16% 16% 16% CCC B 88 88 88 A A A AAA	2015
ISS-oekom≽	<b>=</b> B- / Top 10 %	"Prime" status and industry leader	Corporate Responsibility Prime rated by cekom r o s o a r o h	2013
FTSE Russell	1 3.9 / 79 <sup>th</sup> percentile	Included in FTSE4 Good Index	FTSE4Good	2015
ecovadis	=75 / 98 <sup>th</sup> percentile	-	→75 / 100	2012
vigeeiris	<b>=</b> 60 / 100 − "advanced"	Included in Ethibel and Euronext indices	EURONEXT VIGEQUITIS NOCE EUROPE 120	2014
44 CDD	↑ Climate: B / Range: A to D-	Above global average	B- Climate Water and	d Forests
DRIVING SISTANABLE COOKINES	=- Water B- / Range: A to D-	Forests: above global average Water: below global average	2013	

# **Debt Maturity Profile as of 30 September 2023**



<sup>&</sup>lt;sup>1</sup> financial derivatives with positive fair values reported under other current assets

<sup>&</sup>lt;sup>2</sup> Green Bond as issued under Clariant Green Financing Framework

# **Calendar of Upcoming Corporate Events**

2024

14 March 2024

9 April 2024

30 July 2024

**Integrated Report** 

AGM 2024

Second Quarter / Half Year 2024 Reporting



Fourth Quarter / Full Year 2023 Reporting

30 April 2024

First Quarter 2024 Reporting 29 October 2024

Third Quarter / Nine Month 2024 Reporting

# **The Executive Leadership Team**



Conrad Keijzer
Chief Executive Officer

### **Executive Leadership Team**

### **Executive Steering Committee**



Christian Vang
Business President
CC & Americas



Jens Cuntze
Business President
CA & APAC



Angela Cackovich
Business President
AA & EMEA



Bill Collins
Chief Financial
Officer



Tatiana Berardinelli Chief Human Resources Officer



Judith Bischof General Counsel



Richard Haldimann Chief Technology & Sustainability Officer



Chris Hansen
Chief Corp.
Development Officer

# **IR Contacts**



ANDREAS SCHWARZWÄLDER
Head of Investor Relations

Phone: +41 61 469 63 73

Email: <u>investor-relations@clariant.com</u>



THIJS BOUWENS
Investor Relations Officer

Phone: +41 61 469 63 73

Email: <u>investor-relations@clariant.com</u>

